Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

• DOI: 10.20944/preprints202308.2094.v1
• Publication Date: 2023-08-31T03:19:23Z
• Authors: Ferdinando D’Amico; Virginia Solitano; Fernando Magro; Pablo A. Olivera; Jonas Halfvarson; David T. Rubin; Axel Dignass; Sameer Al Awadhi; Taku Kobayashi; Natalia Sousa Fre...; Marta Calvo; Paulo Gustavo Kotze; Subrata Ghosh; Laurent Peyrin-Bi...; Silvio Danese
• Keywords: Biosimilar; Delphi Method; Delphi; Inflammatory Bowel Diseases

While biologic originators’ patents are expiring, biosimilars emerging to take their place, offering significant cost savings healthcare systems. Many challenges still need be addressed in the clinical practice of inflammatory bowel disease (IBD). A global survey was organized highlight physicians’ current knowledge and beliefs gain insight about practical management remaining concerns obstacles associated with starting a biosimilar, switching from an originator or one biosimilar another (multiple switches reverse switching). Fifteen physicians expertise field IBD 13 countries attended virtual international consensus meeting develop guidance regarding adoption worldwide, considering results. Consensus reached on 10 statements effectiveness, safety, indications rationale, multiple switches, therapeutic drug monitoring biosimilars, non-medical future perspectives.